IL135109A0 - Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function - Google Patents

Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function

Info

Publication number: IL135109A0
Authority: IL; Israel
Prior art keywords: azabenzimidazole; protein kinase; based compounds; threonine protein; kinase function
Prior art date: 1997-09-26

Application number

IL13510998A

Other languages

English (en)

Original Assignee

Asta Medica Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-09-26

Filing date

1998-09-23

Publication date

2001-05-20

1998-09-23 Application filed by Asta Medica Ag filed Critical Asta Medica Ag

1998-09-23 Priority to IL15864998A priority Critical patent/IL158649A0/xx

2001-05-20 Publication of IL135109A0 publication Critical patent/IL135109A0/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

IL13510998A 1997-09-26 1998-09-23 Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function IL135109A0 (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
IL15864998A IL158649A0 (en)	1997-09-26	1998-09-23	Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US6014597P	1997-09-26	1997-09-26
PCT/US1998/019973 WO1999016438A1 (en)	1997-09-26	1998-09-23	Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function

Publications (1)

Publication Number	Publication Date
IL135109A0 true IL135109A0 (en)	2001-05-20

Family

ID=22027657

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
IL15864998A IL158649A0 (en)	1997-09-26	1998-09-23	Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function
IL13510998A IL135109A0 (en)	1997-09-26	1998-09-23	Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function
IL135109A IL135109A (en)	1997-09-26	2000-03-15	Compounds based on azabenzamide, a method, their preparation and the pharmaceutical preparations containing them
IL158649A IL158649A (en)	1997-09-26	2003-10-29	Regulation of the activity of serine / threonine protein kinase using azabenzamide-based compounds

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
IL15864998A IL158649A0 (en)	1997-09-26	1998-09-23	Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
IL135109A IL135109A (en)	1997-09-26	2000-03-15	Compounds based on azabenzamide, a method, their preparation and the pharmaceutical preparations containing them
IL158649A IL158649A (en)	1997-09-26	2003-10-29	Regulation of the activity of serine / threonine protein kinase using azabenzamide-based compounds

Country Status (27)

Country	Link
US (2)	US6093728A (xx)
EP (1)	EP1017384B1 (xx)
JP (1)	JP2001517699A (xx)
KR (1)	KR100547929B1 (xx)
CN (1)	CN1167420C (xx)
AR (1)	AR017266A1 (xx)
AT (1)	ATE281834T1 (xx)
AU (1)	AU748849B2 (xx)
BG (1)	BG64784B1 (xx)
BR (1)	BR9812682A (xx)
CA (1)	CA2305370C (xx)
DE (1)	DE69827516T2 (xx)
DK (1)	DK1017384T3 (xx)
ES (1)	ES2230719T3 (xx)
HU (1)	HUP0004024A3 (xx)
IL (4)	IL158649A0 (xx)
NO (1)	NO325663B1 (xx)
NZ (2)	NZ503432A (xx)
PL (1)	PL191618B1 (xx)
PT (1)	PT1017384E (xx)
RU (1)	RU2230553C2 (xx)
SK (1)	SK285357B6 (xx)
TR (1)	TR200001546T2 (xx)
TW (1)	TW581815B (xx)
UA (1)	UA72448C2 (xx)
WO (1)	WO1999016438A1 (xx)
ZA (1)	ZA988797B (xx)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060142236A1 (en) *	1994-05-31	2006-06-29	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of raf gene expression
US6919366B2 (en) *	1998-05-22	2005-07-19	Avanir Pharmaceuticals	Benzimidazole derivatives as modulators of IgE
US6911462B2 (en) *	1998-05-22	2005-06-28	Avanir Pharmaceuticals	Benzimidazole compounds for regulating IgE
US6384049B1 (en) *	2000-05-25	2002-05-07	The Procter & Gamble Company	Cancer treatment
ES2291455T3 (es) *	2001-03-12	2008-03-01	Avanir Pharmaceuticals	Compuestos de bencimidazol para modular ige e inhibir la proliferacion celular.
TW200304820A (en) *	2002-03-25	2003-10-16	Avanir Pharmaceuticals	Use of benzimidazole analogs in the treatment of cell proliferation
TWI276631B (en) *	2002-09-12	2007-03-21	Avanir Pharmaceuticals	Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
AU2003270426A1 (en)	2002-09-12	2004-04-30	Avanir Pharmaceuticals	PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
WO2005013950A2 (en) *	2003-08-08	2005-02-17	Avanir Pharmaceuticals	Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
GB0423554D0 (en)	2004-10-22	2004-11-24	Cancer Rec Tech Ltd	Therapeutic compounds
US8642278B2 (en) *	2005-11-22	2014-02-04	University Of South Florida	Inhibition of cell proliferation
CA2649994A1 (en)	2006-04-26	2007-11-08	Cancer Research Technology Limited	Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds
RU2478635C2 (ru) *	2006-10-19	2013-04-10	СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи	Гетероарильные соединения, содержащие их композиции и способы лечения с применением этих соединений
EP2134373A4 (en) *	2007-02-28	2014-04-02	Yeda Res & Dev	CORE TARGETING SEQUENCES
CL2008001626A1 (es) *	2007-06-05	2009-06-05	Takeda Pharmaceuticals Co	Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
WO2009025358A1 (ja)	2007-08-23	2009-02-26	Takeda Pharmaceutical Company Limited	複素環化合物およびその用途
WO2009028629A1 (ja) *	2007-08-29	2009-03-05	Takeda Pharmaceutical Company Limited	複素環化合物およびその用途
BRPI0821227A2 (pt)	2007-12-19	2015-06-16	Cancer Rec Tech Ltd	Composto, composição farmacêutica, método para preparar a mesma, uso de um composto, método para tratar uma doença ou distúrbio, para inibir função de raf e para inibir proliferação celular, inibir progressão do ciclo celular, promover apoptose, ou uma combinação de um ou mais dos mesmos
GB0807609D0 (en)	2008-04-25	2008-06-04	Cancer Rec Tech Ltd	Therapeutic compounds and their use
US20100184851A1 (en) *	2008-08-29	2010-07-22	University Of South Florida	Inhibition of cell proliferation
US8110578B2 (en)	2008-10-27	2012-02-07	Signal Pharmaceuticals, Llc	Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
EP2399921B1 (en)	2008-12-01	2015-08-12	Takeda Pharmaceutical Company Limited	Heterocyclic compound and use thereof
JO3101B1 (ar)	2008-12-02	2017-09-20	Takeda Pharmaceuticals Co	مشتقات بنزوثيازول كعوامل مضادة للسرطان
JP2012197231A (ja) *	2009-08-06	2012-10-18	Oncotherapy Science Ltd	Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体
CN106117213B (zh)	2009-10-26	2022-03-18	西格诺药品有限公司	杂芳基化合物及其合成和纯化方法
CN104945401B (zh)	2010-02-01	2017-09-05	癌症研究技术有限公司	Ip化合物及它们在治疗中的应用
TWI713752B (zh)	2011-10-19	2020-12-21	標誌製藥公司	以ｔｏｒ激酶抑制劑治療癌症
US9403829B2 (en)	2011-12-02	2016-08-02	Signal Pharmaceuticals, Llc	Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1H)-one, a solid form thereof and methods of their use
EP2817029B1 (en)	2012-02-24	2019-07-10	Signal Pharmaceuticals, LLC	Methods for treating non-small cell lung cancer using tor kinase inhibitor combination therapy
AU2013203714B2 (en)	2012-10-18	2015-12-03	Signal Pharmaceuticals, Llc	Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
CN105188704B (zh)	2013-01-16	2017-09-19	西格诺药品有限公司	被取代的吡咯并嘧啶化合物、其组合物和使用其的治疗方法
EP2970277B1 (en) *	2013-03-15	2021-07-28	Knopp Biosciences LLC	Imidazo(4,5-b) pyridin-2-yl amides as kv7 channel activators
US9937169B2 (en)	2013-04-17	2018-04-10	Signal Pharmaceuticals, Llc	Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
BR112015026292B1 (pt)	2013-04-17	2022-04-12	Signal Pharmaceuticals, Llc	Uso de 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-il)piridin-3-il)-3,4-dihidropirazino [2,3-b]pirazin-2(1h)- ona e métodos in vitro
BR112015026021A2 (pt)	2013-04-17	2017-07-25	Signal Pharm Llc	terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer
WO2014172436A1 (en)	2013-04-17	2014-10-23	Signal Pharmaceuticals, Llc	Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
CN113730412A (zh)	2013-04-17	2021-12-03	西格诺药品有限公司	用二氢吡嗪并-吡嗪治疗癌症
CN105392499B (zh)	2013-04-17	2018-07-24	西格诺药品有限公司	用于治疗癌症的包含tor激酶抑制剂和胞苷类似物的组合疗法
EA030726B1 (ru)	2013-04-17	2018-09-28	СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи	ФАРМАЦЕВТИЧЕСКИЕ СОСТАВЫ, СПОСОБЫ, ТВЕРДЫЕ ФОРМЫ И СПОСОБЫ ПРИМЕНЕНИЯ, ОТНОСЯЩИЕСЯ К 1-ЭТИЛ-7-(2-МЕТИЛ-6-(1H-1,2,4-ТРИАЗОЛ-3-ИЛ)ПИРИДИН-3-ИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1H)-ОНУ
MX2015015880A (es)	2013-05-29	2016-05-31	Signal Pharm Llc	Composiciones farmaceuticas de 7-(6-(2-hidroxipropan-2-il)piridin- 3-il)-1-((trans)-4-metoxiciclohexil)-3,4-dihidropirazino[2,3-b]pi razin-2(1h)-ona, una forma solida del mismo y metodos de su uso.
US9695402B2 (en)	2013-09-17	2017-07-04	Yeda Research And Development Co. Ltd.	ERK-derived peptides and uses thereof
GB201320732D0 (en)	2013-11-25	2014-01-08	Cancer Rec Tech Ltd	Methods of chemical synthesis
GB201320729D0 (en)	2013-11-25	2014-01-08	Cancer Rec Tech Ltd	Therapeutic compounds and their use
NZ714742A (en)	2014-04-16	2017-04-28	Signal Pharm Llc	Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2015160880A1 (en)	2014-04-16	2015-10-22	Signal Pharmaceuticals, Llc	SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
US9737535B2 (en)	2014-04-16	2017-08-22	Signal Pharmaceuticals, Llc	Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines
WO2015160882A1 (en)	2014-04-16	2015-10-22	Signal Pharmaceuticals, Llc	SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
NZ629796A (en)	2014-07-14	2015-12-24	Signal Pharm Llc	Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
EA201790189A1 (ru)	2014-07-14	2017-11-30	СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи	Способы лечения злокачественного новообразования с использованием замещенных пирролопиримидиновых соединений, композиции на их основе
RS64708B1 (sr)	2014-09-12	2023-11-30	Biohaven Therapeutics Ltd	Benzoimidazol-1,2-il amidi kao aktivatori kv7 kanala
MY198676A (en)	2017-06-22	2023-09-15	Celgene Corp	Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3590045A (en) *	1969-09-25	1971-06-29	Smith Kline French Lab	Certain substituted imidazo (4,5-b)pyridines
BE788065A (fr)	1971-08-26	1973-02-26	Degussa	Nouvelles aza-benzimidazoles et procede pour leur preparation
SE422799B (sv)	1975-05-28	1982-03-29	Merck & Co Inc	Analogiforfarande for framstellning av 1,3-dihydroimidazo (4,5-b)pyridin-2-oner
ES473201A1 (es) *	1977-09-26	1979-03-16	Degussa	Procedimiento para la preparacion de 7-azabencimidazoles
US5217999A (en) *	1987-12-24	1993-06-08	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Styryl compounds which inhibit EGF receptor protein tyrosine kinase
ES2064101T3 (es) *	1990-04-02	1995-01-16	Pfizer	Compuestos de acido bencilfosfonico inhibidores de la quinasa de tirosina.
US5302606A (en) *	1990-04-16	1994-04-12	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
SG64322A1 (en) *	1991-05-10	1999-04-27	Rhone Poulenc Rorer Int	Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
CA2108889A1 (en) *	1991-05-29	1992-11-30	Robert Lee Dow	Tricyclic polyhydroxylic tyrosine kinase inhibitors
AU661533B2 (en) *	1992-01-20	1995-07-27	Astrazeneca Ab	Quinazoline derivatives
RU2155187C2 (ru) *	1992-08-06	2000-08-27	Варнер-Ламберт Компани	Производные индола, их таутомеры, смеси их изомеров или отдельные изомеры и фармацевтически приемлемые соли, фармацевтическая композиция с антиопухолевой или ингибирующей протеин-тирозинкиназу активностью и способ торможения зависящего от протеин-тирозинкиназы заболевания или борьбы с аберрантным ростом клеток млекопитающего или человека.
US5330992A (en) *	1992-10-23	1994-07-19	Sterling Winthrop Inc.	1-cyclopropyl-4-pyridyl-quinolinones
GB9226855D0 (en) *	1992-12-23	1993-02-17	Erba Carlo Spa	Vinylene-azaindole derivatives and process for their preparation
US5582995A (en)	1993-06-11	1996-12-10	The General Hospital Corporation	Methods of screening for compounds which inhibit the direct binding of Ras to Raf
BR9406946A (pt) *	1993-07-06	1996-08-06	Pfizer	Tetra-hidro-pirazolpiridinas bicíclicas
US5645982A (en) *	1993-08-19	1997-07-08	Systemix, Inc.	Method for screening potential therapeutically effective antiviral agents
GB9501567D0 (en) *	1995-01-26	1995-03-15	Pharmacia Spa	Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5880141A (en) *	1995-06-07	1999-03-09	Sugen, Inc.	Benzylidene-Z-indoline compounds for the treatment of disease

1998
- 1998-09-23 AU AU95781/98A patent/AU748849B2/en not_active Ceased
- 1998-09-23 PL PL339744A patent/PL191618B1/pl not_active IP Right Cessation
- 1998-09-23 UA UA2000042349A patent/UA72448C2/uk unknown
- 1998-09-23 RU RU2000110736/15A patent/RU2230553C2/ru not_active IP Right Cessation
- 1998-09-23 JP JP2000513574A patent/JP2001517699A/ja not_active Withdrawn
- 1998-09-23 BR BR9812682-2A patent/BR9812682A/pt not_active Application Discontinuation
- 1998-09-23 CN CNB988107538A patent/CN1167420C/zh not_active Expired - Fee Related
- 1998-09-23 IL IL15864998A patent/IL158649A0/xx not_active IP Right Cessation
- 1998-09-23 DK DK98949464T patent/DK1017384T3/da active
- 1998-09-23 KR KR1020007003192A patent/KR100547929B1/ko not_active Expired - Fee Related
- 1998-09-23 WO PCT/US1998/019973 patent/WO1999016438A1/en not_active Ceased
- 1998-09-23 PT PT98949464T patent/PT1017384E/pt unknown
- 1998-09-23 US US09/160,212 patent/US6093728A/en not_active Expired - Fee Related
- 1998-09-23 CA CA002305370A patent/CA2305370C/en not_active Expired - Fee Related
- 1998-09-23 HU HU0004024A patent/HUP0004024A3/hu unknown
- 1998-09-23 EP EP98949464A patent/EP1017384B1/en not_active Expired - Lifetime
- 1998-09-23 NZ NZ503432A patent/NZ503432A/xx unknown
- 1998-09-23 DE DE69827516T patent/DE69827516T2/de not_active Expired - Fee Related
- 1998-09-23 TR TR2000/01546T patent/TR200001546T2/xx unknown
- 1998-09-23 ES ES98949464T patent/ES2230719T3/es not_active Expired - Lifetime
- 1998-09-23 IL IL13510998A patent/IL135109A0/xx not_active IP Right Cessation
- 1998-09-23 AT AT98949464T patent/ATE281834T1/de not_active IP Right Cessation
- 1998-09-23 SK SK415-2000A patent/SK285357B6/sk unknown
- 1998-09-25 ZA ZA9808797A patent/ZA988797B/xx unknown
- 1998-09-25 TW TW087115979A patent/TW581815B/zh not_active IP Right Cessation
- 1998-09-25 AR ARP980104793A patent/AR017266A1/es unknown
2000
- 2000-03-15 IL IL135109A patent/IL135109A/en unknown
- 2000-03-24 NO NO20001555A patent/NO325663B1/no unknown
- 2000-04-19 BG BG104356A patent/BG64784B1/bg unknown
2002
- 2002-03-15 NZ NZ517808A patent/NZ517808A/en unknown
- 2002-11-15 US US10/294,802 patent/US6855723B2/en not_active Expired - Fee Related
2003
- 2003-10-29 IL IL158649A patent/IL158649A/en unknown

Also Published As

Publication number	Publication date
IL158649A0 (en)	2004-05-12
NZ503432A (en)	2002-11-26
NZ517808A (en)	2003-07-25
JP2001517699A (ja)	2001-10-09
HUP0004024A3 (en)	2001-10-29
EP1017384A1 (en)	2000-07-12
IL158649A (en)	2006-12-10
CA2305370A1 (en)	1999-04-08
WO1999016438A1 (en)	1999-04-08
KR20010015623A (ko)	2001-02-26
TW581815B (en)	2004-04-01
RU2230553C2 (ru)	2004-06-20
PT1017384E (pt)	2005-03-31
BG64784B1 (bg)	2006-04-28
ZA988797B (en)	1999-12-02
NO20001555L (no)	2000-03-24
US6855723B2 (en)	2005-02-15
US6093728A (en)	2000-07-25
NO325663B1 (no)	2008-07-07
CN1278172A (zh)	2000-12-27
PL339744A1 (en)	2001-01-02
CN1167420C (zh)	2004-09-22
NO20001555D0 (no)	2000-03-24
AU748849B2 (en)	2002-06-13
AR017266A1 (es)	2001-09-05
HK1032206A1 (en)	2001-07-13
PL191618B1 (pl)	2006-06-30
SK4152000A3 (en)	2002-02-05
DE69827516D1 (de)	2004-12-16
TR200001546T2 (tr)	2000-10-23
AU9578198A (en)	1999-04-23
IL135109A (en)	2007-07-04
DK1017384T3 (da)	2005-01-31
US20030181480A1 (en)	2003-09-25
KR100547929B1 (ko)	2006-02-02
UA72448C2 (en)	2005-03-15
ATE281834T1 (de)	2004-11-15
DE69827516T2 (de)	2005-12-01
ES2230719T3 (es)	2005-05-01
CA2305370C (en)	2006-11-28
BG104356A (en)	2000-12-29
HUP0004024A2 (hu)	2001-04-28
EP1017384B1 (en)	2004-11-10
BR9812682A (pt)	2000-08-22
SK285357B6 (sk)	2006-11-03

Publication	Publication Date	Title
IL158649A0 (en)	2004-05-12	Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function
ZA988961B (en)	1999-10-04	Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds.
HUS1600018I1 (hu)	2018-05-02	Aril kondenzált azapoliciklusos vegyületek
AU3363599A (en)	1999-10-18	Heterocyclic families of compounds for the modulation of tyrosine protein kinase
AU7282998A (en)	1998-11-27	Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds
EG24041A (en)	2008-04-03	New heterocyclic compounds
GB9715892D0 (en)	1997-10-01	Heterocyclic compounds
IL134086A0 (en)	2001-04-30	Novel spiroazabicyclic heterocyclic compounds
IL132170A0 (en)	2001-03-19	Novel heterocyclic compounds
HUP0103079A3 (en)	2004-03-01	Modulating multiple lineage kinase proteins
ZA981920B (en)	1998-09-07	Novel heterocyclic compounds
AU6049399A (en)	2000-04-03	Serine/threonine protein kinases
GB9803399D0 (en)	1998-04-15	Protein kinase c
AU6421498A (en)	1998-11-24	Serine/threonine protein kinase
GB9713732D0 (en)	1997-09-03	Substituted triazinic compounds
GB9716101D0 (en)	1997-10-01	Fused heterocyclic compounds
ZA985448B (en)	1999-01-19	Novel heterocyclic compounds
ZA983800B (en)	1998-11-06	Novel heterocyclic compounds
ZA983669B (en)	1999-11-01	Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds.
IL136872A0 (en)	2001-06-14	Organosilane compounds
GB9801058D0 (en)	1998-03-18	Heterocyclic compounds
GB9715735D0 (en)	1997-10-01	Heterocyclic compounds
GB9719237D0 (en)	1997-11-12	Heterocyclic compounds
ZA989421B (en)	1999-04-21	Heterocyclic compounds
GB9702945D0 (en)	1997-04-02	Heterocyclic compounds

Legal Events

Date	Code	Title
2002-06-30	HP	Change in proprietorship
2007-12-03	FF	Patent granted
2008-01-06	KB	Patent renewed
2009-12-24	MM9K	Patent not in force due to non-payment of renewal fees